Loading publications…
The last 5 uploaded publications
Association of early PSMA upregulation with duration of response to enzalutamide with or without [177Lu]Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: Findings from the randomised, phase 2, ENZA-p trial (ANZUP 1901)
Louise Emmett, Mina Swiha, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Anthony M. Joshua, Andrew Nguyen, Andrew Weickhardt, Sze Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Sarennya Pathmanandavel, Narjess Ayati, Michael S. Hofman, Shahneen Sandhu, Andrew Martin, Hayley Thomas, Martin R. Stockler, Ian D. Davis (2025). Association of early PSMA upregulation with duration of response to enzalutamide with or without [177Lu]Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: Findings from the randomised, phase 2, ENZA-p trial (ANZUP 1901). , DOI: https://doi.org/10.21203/rs.3.rs-6307229/v1.
Preprint62 days agoPredictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ <sup>177</sup> Lu] Lu-PSMA-617 (ANZUP1901).
Louise Emmett, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Anthony M. Joshua, Andrew Nguyen, Andrew Weickhardt, Sze Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Michael S. Hofman, Shahneen Sandhu, Andrew Martin, Hayley Thomas, Ian D. Davis, Martin R. Stockler (2025). Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ <sup>177</sup> Lu] Lu-PSMA-617 (ANZUP1901).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5011.
Article62 days agoFirst-in-human results of terbium-161[ <sup>161</sup> Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.
James Buteau, Louise Kostos, Price Jackson, Lachlan McIntosh, Ramin Alipour, Timothy Akhurst, Michal Eifer, Brittany Emmerson, Mohammad B. Haskali, Kerry Jewell, Raghava Kashyap, Grace Kong, Declan G. Murphy, Aravind S. Ravi Kumar, Javad Saghebi, Shahneen Sandhu, Ben Tran, Jing Xie, Arun Azad, Michael S. Hofman (2025). First-in-human results of terbium-161[ <sup>161</sup> Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5010.
Article62 days agoLutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
Edmond M. Kwan, Sarah W.S. Ng, Sofie H. Tolmeijer, Louise Emmett, Shahneen Sandhu, James Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Vinod Vijay Subhash, Sze-Ting Lee, Andrew M. Scott, Andrew Martin, Martin R. Stockler, Gráinne Donnellan, Matti Annala, Cameron Herberts, Ian D. Davis, Michael S. Hofman, Arun Azad, Alexander W. Wyatt (2025). Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. , DOI: https://doi.org/10.1038/s41591-025-03704-9.
Article62 days agoClonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving <sup>177</sup> Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).
Aslı D. Munzur, Cameron Herberts, Edmond M. Kwan, Louise Emmett, Shahneen Sandhu, James Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Sze Ting Lee, Andrew M. Scott, Andrew Martin, Martin R. Stockler, Alison Yan Zhang, Scott Williams, Jack V. W. Bacon, Arun Azad, Ian D. Davis, Michael S. Hofman, Alexander W. Wyatt (2025). Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving <sup>177</sup> Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5020.
Article62 days ago